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Abstract
Background and Aim
Liver biopsy (LB) has lost popularity to stage liver fibrosis in the era of highly effective anti-
hepatitis C virus (HCV) therapy, yet diagnosis of persistent cirrhosis may have important
implications following HCV eradication. As performance of serological non-invasive tests
(NITs) to predict residual fibrosis in non-viremic HCV patients is unknown, we investigated
accuracy of NITs to predict residual fibrosis in cirrhotics after a sustained virological
response (SVR) to interferon (IFN).
Methods
Thirty-eight patients with a pre-treatment histological diagnosis of cirrhosis and a 48–104
months post-SVR LB were tested with APRI, CDS, FIB-4, FibroQ, Forns Score, GUCI
Index, King Score, Lok Index, PLF, ELF. In 23 (61%) patients, cirrhosis had histologically
regressed.
Results
All NITs values declined after SVR without any significant difference between regressors
and non-regressors (AUROC 0.52–0.75). Using viremic cut-offs, PPV ranged from 34% to
100%, with lower NPV (63% - 68%). NITs performance did not improve using derived cut-
offs (PPV: 40% - 80%; NPV: 66% - 100%). PLF, which combines several NITs with transient
elastography, had the best diagnostic performance (AUROC 0.75, Sn 61%, Sp 90%, PPV
80%, NPV 78%). After treatment, none of the NITs resulted significantly associated with
any of the histological features (activity grade, fibrosis stage, area of fibrosis).
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Conclusions
The diagnostic estimates obtained using both viremic and derived cut-off values of NITs
were suboptimal, indicating that none of these tests helps predicting residual fibrosis and
that LB remains the gold standard for this purpose.
Introduction
The long-standing dogma that cirrhosis is an irreversible condition has been repeatedly chal-
lenged in last decades. Indeed many studies in hepatitis C (HCV) patients with a sustained
virological response (SVR) to Interferon (IFN)-based regimens showed cirrhosis regression in
30% to 60% patients 3 to 5 years after SVR [1–16]; this histological outcome was associated
with reduced risk of developing hepatocellular carcinoma (HCC), hepatic decompensation and
variceal bleeding, while, on the contrary, a clinical benefit was not observed in SVR patients
with residual cirrhosis [9]. These findings rose the argument about need for assessing residual
cirrhosis in HCV patients with an SVR, in order to deliver accurate prognosis and optimize
clinical management. Indeed, all SVR cirrhotic patients are currently recommended to keep
lifelong surveillance for HCC with abdominal ultrasound (US) every 6 months [17], as these
patients still carry a 0.6%-1.2% yearly risk of HCC [13,16,18,19]. The demonstration of cirrho-
sis regression would allow for tailored surveillance intervals, as the reduced risk of HCC in cir-
rhosis regressors would make US surveillance every 6 months non cost/effective.
Liver biopsy (LB) currently represents the gold standard for accurately assessing liver fibro-
sis stage and consequently identifying cirrhosis regression, however it has limited application
because it is an invasive procedure, poorly accepted by patients and ultimately carries a risk of
complications [20,21]. Moreover, LB accuracy is biased by heterogeneous deposition of fibrosis
in the liver, sampling error and inter-observer variability [22,23]. These drawbacks highlight
the need for alternative non-invasive methods to assess fibrosis stage following an SVR. In this
setting, we previously demonstrated that transient elastography (TE) has low diagnostic accu-
racy in identifying residual cirrhotic patients after an SVR, mainly as a consequence of fibrosis
remodeling [24]. The aim of this study was to investigate the diagnostic performance of most
popular serological markers of hepatic fibrosis in a unique albeit small group of patients with
histologically documented cirrhosis who underwent a second liver biopsy 5 years after achiev-
ing an SVR to IFN-based therapies.
Material and Methods
Patient population
This study is a post-hoc analysis of a cohort study of 38 HCV cirrhotic patients, who underwent
a LB following an SVR to assess histological modifications associated with viral clearance [12].
The first LB was performed within 12 months before anti-HCV treatment, while the second at
least 4 years after the SVR [12]. Exclusion criteria were HBV or HIV co-infection,>40 g/day
alcohol intake, malignancies, contraindication to LB. At the time of post-SVR LB, all patients
had liver stage concomitantly assessed through TE and the following serological non-invasive
tests (NITs): APRI, CDS, FIB-4, FibroQ, Forns Score, GUCI Index, King Score, Lok Index, PLF
and ELF (seeMaterial and Methods Section). All patients gave their written informed consent
to use of their medical records and perform the post-treatment LB for the study, which was
approved by the Institutional Review Board of the Department of Internal Medicine.
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Histological assessment
All pre-treatment LBs were performed with a cutting needle (Tru-cut 16 G, TSK Laborato-
ries, Tokyo, Japan), whilst a Menghini-like semiautomatic biopsy device (Biomol 16 G, HS
Hospital Service, Latina, Italy) was used for post-treatment samples. Liver biopsies were con-
sidered adequate for histological analysis if longer than 10 mm and/or carrying at least 12
portal tracts. All biopsies were read independently by two expert Pathologists blinded to any
clinical information. Fibrosis stage was assessed according to the METAVIR scoring system
[25], while hepatic inflammation was evaluated according to both METAVIR and Ishak
grading systems [25,26]. Cirrhosis regression was defined as decrease from F4 to F3 or less
when comparing pre- and post-treatment LBs [12]. Area of fibrosis was calculated by using
the HISTOLAB1 software (ALPHELYS, Plaisir, France), and was defined as ratio of fibrous
tissue area stained with picrosirius red (%) upon the total tissue surface, as previously
described [12].
Non-invasive measurements
Transient elastography. Transient elastography was performed as already described [27];
liver stiffness measurement (LSM) was expressed in kiloPascal (kPa) as the median value of the
successful measurements. As previously published [28] TE threshold of 12 kPa was used for
the diagnosis of cirrhosis.
Serological non-invasive tests. The following serological indirect and direct markers of
liver fibrosis [29] were tested according to their formula:
1. Indirect serological markers
APRI (AST to platelet ratio): AST levels (× ULN)/platelets count (103/l) × 100
CDS (Cirrhosis Discriminate Score): calculated by summing the scores awarded for the fol-
lowing laboratory results (Table 1)
FIB-4: [age (yr) × AST (U/l)]/[(PLT (109/l)] × [ALT (U/l)1/2]
FibroQ: [(10 x age (yr)) x AST (U/l) x PT INR)/[PLT (109/l) x ALT (U/l)]
Forns Score: 7.811–3.131 × ln [PLT (109/l)] × 0.781 ln [GGT (U/l)] + 3.467 × ln [age (yr)] -
0.014 [cholesterol (mg/dl)]
GUCI (Goteborg University Cirrhosis Index): (AST/ULN) × INR × 100/PLT (109/l)
King Score: age (yr) × AST (U/l) × INR/PLT (109/l)
Lok Index:– 5.56–0.0089 × PLT (103/mm) + 1.26 × AST/ALT ratio + 5.27 × INR
PLF (Predicted Liver Fibrosis): 0.956 + 0.084 × TE –0.004 × King Score + 0.124 × Forns
Score + 0.202 × APRI Score.
Reference cut-offs for cirrhosis, obtained from literature, were APRI>1.5, CDS8, Fib4
>3.25, FibroQ>2.6, Forns Score6.9, GUCI>0.26, King Score16.7, Lok Index>0.5
and PLF2.98 [30–39].
2. Direct serological markers. Enhanced Liver Fibrosis (ELF) test combines semiquantitative
serum measurements of tissue inhibitor of metallo-proteinases-1 (TIMP-1), amino-terminal
propeptide of type III collagen (PIIINP) and hyaluronic acid (HA). ADVIA Centaur CP
Table 1. Cirrhosis Discriminate Score (CDS) calculation.
Parameters 0 1 2 3 4 5 6
INR <1.1 1.1–1.4 >1.4
ALT/AST >1.7 1.7–1.2 1.19–0.6 <0.6
PLT /mm3 >340 340–280 279–220 219–160 159–100 99–40 <40
doi:10.1371/journal.pone.0155967.t001
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immunochemical analyzer was used according to manufacturer’s instructions and the ELF
score was calculated by the following equation: -7.412 + [ln(HA)0.681] + [ln(PIIINP)
0.775] + [ln(TIMP-1)0.494] + 10 [40–43]. Four cut-offs (9.3, 9.8, 10.3, 11.3) were used for
the diagnosis of cirrhosis (F4), since a univocal standard threshold for F4 has not been vali-
dated [41–44].
Statistical analysis
Comparisons between groups were made by using the Mann–Whitney U or the Student’s-t
tests for continuous variables, and the χ2 or Fisher test for categorical data. A probability value
of p<0.05 was considered statistically significant. The diagnostic accuracy of non-invasive
markers in SVR patients was expressed as sensitivity, specificity, positive and negative likeli-
hood ratios (LR+ and LR-), positive and negative predictive values (PPV and NPV), using
receiver operating characteristic (ROC) curves analysis. The accuracy of NIT and TE to identify
cirrhosis has been assessed. A receiver operating characteristic (ROC) curve analysis was per-
formed and the area under the ROC curve (AUC) has been reported.
Categorical data were reported as counts (percentages) and continuous variables as mean
(standard deviation) or median (interquartile range, IQR), as appropriate.
Uni- and multivariate linear regression analyses were performed to assess the ability of the
NITs (APRI, CDS, FIB-4, FIBRO-Q, FORNS score, GUCI index, King score, Lok index, ELF,
PLF) in predicting the histological features (i.e. activity grade, fibrosis stage, area of fibrosis).
Also TE was included in the analysis. Only those parameters that showed a statistically signifi-
cant result at the univariate analysis were entered in the multivariate analysis. The performance
of the linear models was evaluated by the determination coefficient (R2). Two analyses were
performed considering, in separate, pre- and post-treatment (SVR) data. P values lower than
0.05, two sided, were considered statistically significant. All statistical analyses were performed
with SAS statistical software (release 9.4; SAS Institute Inc, Cary, NC).
Results
Patient population
Clinical data were available at baseline and at the time of second LB, 61 (48–104) months after
the SVR. Thirty-three (89%) patients had also a post-SVR LSM, while none had a baseline TE
assessment. At post-SVR LB, 35 (92%) patients showed normal transaminases whereas 36
(95%) had a platelet count higher than 100,000/mm3. Post-SVR liver biopsies showed cirrhosis
regression in 23 (61%) patients: F3 in 14 (61%), F2 in 7 (30%), and F1 in 2 (9%). Cirrhosis per-
sisted in the remaining 15 (39%). No significant clinical differences were observed between
patients staged F4 or<F4, after treatment (Table 2).
Indirect markers of fibrosis
NITs values at post-SVR LB and their reference cut-offs for the diagnosis of cirrhosis are
shown in Table 3. Forns Score and PLF were calculated in 33 (87%) patients with available cho-
lesterol and TE values.
Apart from PLF, NITs values did not significantly differ in regressed and non-regressed
patients (Table 3), and also when stratifying data according to post-SVR fibrosis stage [(F1 vs.
F2 vs. F3 vs. F4): APRI p = 0.14, CDS p = 0.35, FIB-4 p = 0.27, FibroQ p = 0.37, Forns Score
p = 0.18, GUCI p = 0.16, King Score p = 0.18, Lok p = 0.20], due to an extensive overlap of
NITs values across all stages of fibrosis (Figs 1 and 2). PLF was the only NIT to show
Fibrosis Biomarkers to Assess Cirrhosis Regression
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significant differences when comparing fibrosis stages at post-SVR LB (F4 vs.<F4: p = 0.01; F4
vs. F3 vs. F2 vs. F1: p = 0.01) (Table 3, Fig 2).
When analyzing diagnostic performances according to ROC curves generated on reference
cut-offs, all NITs demonstrated low diagnostic accuracy in identifying patients with residual
cirrhosis after the SVR. Indeed, due to low sensitivity and specificity, AUROC ranged from
Table 2. Patients' characteristics at the time of post-SVR liver biopsy.
Feature Overall Regressors Non-Regressors p-value§
(n = 38) (n = 23) (n = 15)
Males* 24 (63%) 15 (65%) 9 (60%) 1.0
Age, years** 66 (46–75) 64 (46–75) 64 (56–72) 0.98
Body weight, Kg** 75 (50–98) 73 (52–90) 73 (55–93) 0.53
BMI > 25 kg/m2 * 16 (42%) 12 (52%) 6 (40%) 0.60
pnALT±* 35 (92%) 21 (91%) 14 (93%) 1.0
PLT > 100x103/mm3* 36 (95%) 22 (96%) 15 (100%) 1.0
INR < 1.2 38 (100%) 23 (100%) 15 (100%) 1.0
Liver core size, mm** 30 (10–45) 30 (15–50) 30 (10–45) 0.22
Fibrosis stage 0.31
F0 0 (0%) 0 (0%) 0 (0%)
F1 2 (5%) 2 (9%) 0 (0%)
F2 7 (18%) 7 (30%) 0 (0%)
F3 14 (37%) 14 (61%) 0 (0%)
F4 15 (40%) 0 (0%) 15 (100%)
§ p-value: regressors vs. non-regressors
*number (%)
** median (range)
± pn: persistent normal
doi:10.1371/journal.pone.0155967.t002
Table 3. Median# NIT values at post-SVR liver biopsy and reference cut-offs for the diagnosis of cirrhosis.
Test Reference Overall Regressors Non-Regressors p-value
Cut-off for F4 (n = 38) (n = 23) (n = 15)
APRI  1.5 0.3 (0.2–0.9) 0.3 (0.2–0.9) 0.3 (0.2–0.8) 0.48
CDS > 8 5 (2–7) 5 (2–6) 5 (3–7) 0.49
FIB-4 > 3.25 1.7 (0.8–3.7) 1.7 (0.8–2.7) 1.7 (1.1–3.7) 0.38
FibroQ > 2.6 3.9 (1.5–7.9) 3.9 (1.5–6.3) 4.0 (1.7–7.9) 0.26
Forns Score* > 6.9 5.1 (3.1–8.5) 5.1 (3.1–8.5) 5.3 (4.0–8.0) 0.83
GUCI Index > 0.26 0.4 (0.2–1.0) 0.4 (0.18–0.95) 0.4 (0.21–0.90) 0.56
King Score > 16.7 7.7 (3.8–20.6) 7.7 (3.8–16.9) 7.7 (4.7–20.6) 0.48
Lok Index > 0.5 0.4 (0.1–0.7) 0.4 (0.1–0.6) 0.4 (0.1–0.7) 0.24
PLF* > 2.98 2.5 (1.7–5.0) 2.5 (1.7–5.0) 2.5 (2.2–4.7) 0.01
ELF** >9.3, >9.8 8.6 (6.8–10.0) 8.6 (7.0–10.0) 8.4 (6.8–9.9) 0.70
>10.3, >11.3
# Results are reported as median (range) values
* Calculated in 33 patients for whom valid TE assessments and/or cholesterol values were available
** Calculated in 29 patients
doi:10.1371/journal.pone.0155967.t003
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0.51 (CDS) to 0.75 (PLF) (Table 4). NITs accuracy remained low also when using the derived
thresholds, obtained by combining the best sensitivity/specificity, with PPV values ranging
between 40% (CDS) and 80% (FIB-4 and PLF), and NPV between 66% (APRI and Lok Index)
and 100% (CDS) (Table 4). Therefore, 5% to 40% of SVR patients were misclassified as regres-
sors (<F4) by NITs, despite cirrhosis persistence at post-SVR LB.
NITs values at baseline are reported in Table 5. Most NITs showed a significant post-treat-
ment decrease (Table 5; Figs 3 and 4), except for CDS, FibroQ and Lok Index.
Before treatment, none of the NITs showed any correlation with the most important histo-
logical features (i.e. fibrosis, activity, area of fibrosis). After treatment, some of the NITs (CDS,
FIB-4, FibroQ, PLF) showed a correlation with the morphometric area of fibrosis, only; how-
ever, this correlation was lost at multivariate analysis (Table 6).
Direct marker of fibrosis: ELF test
ELF test was assessed in 29 (76%) patients at baseline and after the SVR. Median post-treat-
ment value was 8.6 (6.8–10.0) (Table 3), without differences between regressors and non-
regressors (8.6 vs. 8.4, p = 0.70) and across all stages of fibrosis (F1 vs. F2 vs. F3 vs. F4: p = 0.17)
Fig 1. Non-invasive Tests (NITs) values stratification according to post-SVR fibrosis stage.
doi:10.1371/journal.pone.0155967.g001
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Fig 2. Non-invasive Tests (NITs) values stratification according to post-SVR fibrosis stage.
doi:10.1371/journal.pone.0155967.g002
Table 4. Non-invasive tests (NITs) diagnostic accuracy for the identification of patients with residual cirrhosis.
Test Cut-off Patients Sens Spec LR+ LR- PPV NPV AUROC
(n) (%) (%) (%) (%) (95%CI)
APRI > 0.5 9 91 27 3.0 0.8 47 66 0.58 (0.39–0.75)
>1.5 0 - - - - - -
CDS > 2 37 100 4.3 1.03 0.001 40 100 0.51 (0.35–0.68)
>8 0 - - - - - -
FIB-4 > 2.3 7 27 96 6.1 0.7 80 67 0.59 (0.41–0.74)
> 3.25 2 6 100 - 0.9 100 62
FibroQ > 5.2 10 40 87 3.0 0.60 67 69 0.58 (0.41–0.74)
> 2.6 29 80 26 1.1 0.7 41 67
Forns Score > 6.4 7 38 90 3.8 0.6 71 69 0.56 (0.37–0.73)
> 6.9 6 23 90 2.3 0.8 60 64
Guci Index > 0.52 9 33 87 2.5 0.7 62 68 0.56 (0.39–0.72)
> 0.26 29 80 26 1.1 0.7 41 68
King Score > 10.1 9 46 87 3.1 0.6 68 69 0.59 (0.40–0.75)
> 16.7 3 13 100 - 0.8 100 63
Lok Index > 0.5 9 27 91 3.0 0.8 67 66 0.57 (0.40–0.73)
PLF > 2.6 14 61 90 5.8 0.4 80 78 0.75 (0.57–0.89)
> 2.98 4 31 95 6.1 0.7 80 68
ELF Score > 8.1 18 60 74 2.3 0.5 54 78 0.63 (0.43–0.80)
> 9.8 2 90 10 1.1 0.9 34 67
Sn: Sensitivity; Sp: Speciﬁcity; LR+: positive likelihood ratio; LR-: negative; likelihood ratio; PPV: positive predictive value, NPV: negative predictive value.
In bold are reported the diagnostic estimates according to the cut-off maximizing sensitivity and speciﬁcity derived from present data. In plain text the
results according to the cut off reported in the literature.
doi:10.1371/journal.pone.0155967.t004
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Table 5. Non-invasive tests (NITs) values before and after treatment.
Test Baseline SVR p-value
APRI 2.0 (0.2–16.4) 0.3 (0.2–0.9) <0.0001
CDS 5 (1–8) 5 (2–7) 0.96
FIB-4 2.9 (0.4–17.3) 1.7 (0.8–3.7) <0.0001
FibroQ 2.8 (0.6–13.6) 3.9 (1.5–7.9) 0.06
Forns Score* 7.4 (2.3–10.0) 5.1 (3.1–8.5) <0.0001
GUCI Index 2.1 (0.2–20.2) 0.4 (0.2–1) <0.0001
King Score 38.3 (3.4–37.4) 7.7 (3.8–20.6) <0.0001
Lok Index 0.4 (0–0.9) 0.4 (0.1–0.7) 0.33
PLF na 2.5 (1.7–5.0) na
ELF** 10.7 (7.9–14) 8.6 (6.8–10) <0.0001
* Calculated in 33 patients for whom cholesterol values were available
** Calculated in 29 patients
doi:10.1371/journal.pone.0155967.t005
Fig 3. Non-invasive tests (NITs) values distribution at baseline and after an SVR.
doi:10.1371/journal.pone.0155967.g003
Fibrosis Biomarkers to Assess Cirrhosis Regression
PLOS ONE | DOI:10.1371/journal.pone.0155967 June 15, 2016 8 / 14
(Fig 2). After the SVR, most patients had ELF test values below the 4 cut-offs suggested for the
diagnosis of cirrhosis: 25 (86%) patients were< 9.3, 26 (90%)< 9.8, 29 (100%)< 10.3 and 29
(100%)<11.3; therefore ELF diagnostic accuracy could not be assessed according to the refer-
ence cut-offs. When trying to derive a new cut-off with the best sensitivity [60% (18.7–81.3)]
and specificity [74% (43.4–87.4)], that resulted 8.1 in our cohort, it still carried a suboptimal
performance (AUROC 0.63) for identifying residual cirrhosis (Table 4). According to this cut-
off, 5/18 (28%) patients were correctly classified as cirrhotics.
Before treatment, 25 (86%), 20 (69%) 17 (59%) and 5 (17%) patients were correctly classi-
fied as cirrhotics, according to the 9.3, 9.8, 10.3 and 11.3 cut-offs. Pre-treatment median ELF
value was 10.7 (7.9–14), similar in regressors and non-regressors (10.6 vs. 10.8; p = 0.63). At
the time of post-SVR LB, median values declined both in patients with and without cirrhosis
regression (10.7 vs. 8.4, p<0.0001; 10.6 vs. 8.6, p = 0.0015) (Table 5; Fig 4).
At linear regression analysis, ELF values did not correlate with any of the histological
parameters as assessed at LB (activity, fibrosis, area of fibrosis), both at baseline and after the
achievement of an SVR (Table 6).
Discussion
In this proof of concept study about diagnostic accuracy of serological assays for liver fibrosis,
all tests failed to separate SVR patients with residual cirrhosis from minor levels of fibrosis.
Fig 4. Non-invasive tests (NITs) values distribution at baseline and after an SVR.
doi:10.1371/journal.pone.0155967.g004
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Cumulatively, the diagnostic accuracy of these tests by AUROC ranged from 0.51 and 0.75,
whereas, individually, none had a cut-off value that could distinguish between different stages
of fibrosis according to METAVIR.
In HCV patients, serological markers of liver fibrosis are becoming increasingly popular, as
they have shown satisfactory accuracy for liver fibrosis staging, with AUROC ranging between
0.78 and 0.89 according to different studies [29, 45]. However, the performance of serological
tests in HCV patients is lower than TE [28,29,45]. We previously demonstrated that TE failed
to identify residual cirrhosis after the SVR using the classical viremic TE cut-off of 11.9 kPa
[24], speculating that the reduced TE accuracy in non-viremic patients could be the conse-
quence of fibrosis remodeling occurring after the SVR. The present study focuses on this same
subgroup of patients who were evaluated with both direct and indirect serological markers of
fibrosis. Nine indirect tests failed to identify patients with residual cirrhosis, showing lower
diagnostic accuracy in comparison with their performance reported in viremic patients [29].
This poor diagnostic accuracy was in line with the reduced TE performance in this non-viremic
population (AUROC serum assays vs. TE: 0.51–0.75 vs. 0.75) [24]. The loss in diagnostic accu-
racy was probably driven by the normalization of biochemical parameters that are considered
in each test assessed, thus confirming a previous report by Sebastiani et al, who showed poor
performance of APRI, AAR, Forns’ Index, Fibrotest and Fibroindex in 80 viremic patients with
persistently normal transaminase values [46]. On the other hand, a recent study in 115 patients
tested with APRI, FIB-4 and Forns Score 6 years after the SVR found increased values in paral-
lel with histological fibrosis stage (p<0.0001), however with low specificity and PPV [47].
These findings discrepant from our study could be mainly explained by differences in patient
demography, stage of fibrosis and cumulative analysis of residual F3 and F4 stages.
To overcome the pitfalls of a single-test approach in a relatively small study, we tested
whether the combination of different serological tests and TE resulted in improved diagnostic
accuracy. This notwithstanding, PLF, which combines four indirect markers of fibrosis and TE,
showed poor diagnostic accuracy, although it carried the best performance among all tests. Dif-
ferences observed in PLF values between regressors and non-regressors (p = 0.01) and across
all stages of fibrosis (p = 0.01) were likely consequence of the inclusion of TE values in the test
formula, since TE values significantly separated F4 from<F4 patients (p = 0.01) and correlated
Table 6. Correlation between NITs and TE and histological features at univariate linear regression analysis.
Pre-treatment Post-treatment Pre-Treatment Post-Treatment Pre-treatment Post-Treatment
Tests p-value p-value p-value p-value r2 p-value r2 p-value
APRI 0.69 0.38 - 0.56 0.00001 0.99 0.08 0.08
CDS 0.56 0.32 - 0.57 0.002 0.77 0.17 0.04
FIB-4 0.59 0.18 - 0.20 0.003 0.91 0.21 0.003
FibroQ 0.82 0.15 - 0.14 0.011 0.52 0.14 0.01
Forns Score 0.25 0.36 - 0.72 0.0003 0.90 0.10 0.06
GUCI Index 0.65 0.62 - 0.54 0.0007 0.95 0.08 0.07
King Score 0.58 0.40 - 0.32 0.14 0.14 0.14 0.01
Lok Index 0.42 0.06 - 0.23 0.03 0.25 0.08 0.07
PLF 0.17 0.53 - 0.09 0.0003 0.97 0.30 0.0009
ELF 0.17 0.83 - 0.69 0.11 0.06 0.08 0.11
TE - 0.58 - 0.07 - - 0.34 0.0004*
* Only TE maintained its statistical signiﬁcance at multivariate analysis
TE: Transient Elastography
doi:10.1371/journal.pone.0155967.t006
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with post-SVRMETAVIR stage (r = 0.56, p = 0.001). Not surprisingly, PLF diagnostic perfor-
mance was close to that reported for TE in the same cohort in the previous study (AUROC
PLF vs. TE: 0.75 vs. 0.77) [24].
Since indirect serological tests are mostly based upon biochemical parameters of liver
inflammation, which do not directly reflect extracellular matrix (ECM) remodeling, we also
tested the diagnostic accuracy of ELF test, a direct marker of liver fibrosis that could be an ideal
candidate for our study purposes. Indeed, ELF formula includes specific compounds of the
ECM (TIMP-1, PIIINP, HA), which could be more sensitive to hepatic fibrosis rearrangement
occurring after HCV eradication. Although we were not able to calculate ELF values for all the
patients included in this study, we observed that these values were significantly reduced in
post-SVR assessment compared to pre-treatment sampling. ELF diagnostic performance for
identifying residual cirrhosis was sub-optimal in line with other indirect tests. Even the 8.1
derived cut-off did not further improve ELF diagnostic accuracy (AUROC 0.63). Another
study in 81 SVR patients (22% with cirrhosis) found lower ELF values at follow-up than at
baseline, while median ELF values in SVR patients were lower than in non-responder patients
[48]. However, this study was flawed by the lack of a histological reference standard.
While a reduction of serum tests for fibrosis following an SVR has already been reported in
HCV patients [47,49], the present study has the merit to correlate serological tests with post-
treatment stages of liver fibrosis. Indeed, identification of residual cirrhotics in SVR patients
bears clinical interest, since cirrhotic patients who achieve an SVR following antiviral treat-
ments are currently maintained under surveillance due to their residual risk of HCC [17]. A
few years ago, Mallet and colleagues demonstrated that patients who achieved cirrhosis regres-
sion after an SVR remained free from liver-related complications in the following 5 years [9]
whilst HCC developed in patients with persistent cirrhosis, only. Thus, assessment of post-SVR
fibrosis stage might help individualizing the surveillance algorithm in patients with a pre-treat-
ment diagnosis of cirrhosis who achieved viral eradication, although this individual approach
is not recommended by international societies [17]. A point which needs clarifications is also
whether serum assays of liver fibrosis predict long-term outcome and prognosis of SVR
patients as they do with non-viremic patients [41,50]. By the same token, it could be of interest
to identify post-SVR cut-offs of fibrosis tests predicting clinical events during surveillance. In
our small study, we recorded no liver-related events over a 5-year follow-up, thus preventing
the possibility to correlate post-SVR fibrosis stage with clinical outcomes, or to identify those
patients at risk of complications according to their post-treatment values of serum tests. Due to
the lack of robust studies assessing the accuracy of non-invasive tests in staging post-SVR fibro-
sis and/or predicting clinical events after HCV eradication, international guidelines do not rec-
ommend their use in tailoring the management of post-treatment follow-up [45].
We acknowledge weaknesses of our study that may ultimately affect the strength of our con-
clusions. No doubts that sample size is one such weakness, but it was to some extent the result
of our stringent criteria of patient selection in terms of well-compensated patients fitting IFN-
based therapy, who gave their informed consent to perform a second liver biopsy and the long
term surveillance of 5 year on average post-SVR. In addition, for some of these patients Forns
Score, PLF and ELF tests were not available, thus probably limiting the accuracy of their predic-
tive value among this cohort. Finally, the retrospective design of the study prevented the
dynamic study of serum tests of fibrosis. On the other hand, we think that these cons are coun-
terbalanced by several strengths including the single center design in which liver biopsies were
collected before treatment and 5 years following an SVR, and read by two expert pathologists
blinded to any clinical features.
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In conclusion, this study demonstrates that serological biomarkers of liver fibrosis failed to
stratify SVR patients by degree of residual fibrosis and, most important, did not allow identifi-
cation of patients with residual cirrhosis following an SVR.
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